Comparative Pharmacology
Head-to-head clinical analysis: CUPRIC CHLORIDE IN PLASTIC CONTAINER versus MANGANESE CHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUPRIC CHLORIDE IN PLASTIC CONTAINER versus MANGANESE CHLORIDE IN PLASTIC CONTAINER.
CUPRIC CHLORIDE IN PLASTIC CONTAINER vs MANGANESE CHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Copper is an essential trace element that serves as a cofactor for numerous enzymes, including cytochrome c oxidase, superoxide dismutase, ceruloplasmin, lysyl oxidase, and dopamine beta-hydroxylase. It is critical for mitochondrial respiration, antioxidant defense, connective tissue cross-linking, neurotransmitter synthesis, and iron homeostasis. Cupric chloride provides ionic copper for these physiological processes.
Manganese chloride dissociates to provide manganese (Mn²⁺), a cofactor for enzymatic reactions including superoxide dismutase (mitochondrial), pyruvate carboxylase, and arginase. It participates in carbohydrate and lipid metabolism, bone development, and antioxidant defense.
0.5-2.5 mg copper per day intravenously as a supplement to parenteral nutrition.
Intravenous, 0.1 to 0.4 mg/mL as additive to parenteral nutrition, typically 1 to 5 mg per day depending on clinical status and serum levels. Frequent monitoring of manganese levels recommended.
None Documented
None Documented
Terminal elimination half-life of copper is approximately 2-4 weeks (13-28 days) in humans, reflecting slow turnover from tissue stores, particularly liver and brain. This long half-life is clinically important for cumulative toxicity risk.
Terminal elimination half-life: 12-40 days (varies with body stores and nutritional status; prolonged in hepatic impairment due to reduced biliary clearance).
Primarily renal; approximately 80% of absorbed copper is excreted in bile, with fecal loss accounting for the majority (about 80-90%) of total elimination. Urinary excretion is minimal (<5%) under normal conditions.
Renal (biliary/fecal minimal): ~90% of absorbed manganese excreted in bile into feces, with <5% renal excretion; in parenteral administration, renal elimination is negligible as manganese is predominantly cleared via hepatobiliary system.
Category C
Category C
Mineral Supplement
Mineral Supplement